Skip to main content
Bioversys N logo

Bioversys N — Investor Relations & Filings

Ticker · BIOV ISIN · CH0210362643 LEI · 894500UFIGC75NPZEZ68 SW Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2025-02-13 Board/Management Inform…
Country CH Switzerland
Listing SW BIOV

About Bioversys N

https://www.bioversys.com/

Bioversys is a clinical-stage biopharmaceutical company focused on the research and development of novel antibacterial therapies to combat the global threat of antimicrobial resistance (AMR). The company develops small molecule drugs that act on novel bacterial targets through innovative modes of action. Its clinical pipeline includes BV100, a treatment for serious hospital infections caused by Acinetobacter baumannii, and Alpibectir, a novel potentiator for multidrug-resistant tuberculosis (MDR-TB). Both candidates are in Phase 2 clinical development. The company's earlier-stage portfolio includes BV200, an anti-virulence compound for Staphylococcus aureus infections, and BV500 for Nontuberculous mycobacteria (NTM) infections, addressing critical unmet medical needs.

Recent filings

Filing Released Lang Actions
Commercial register
Board/Management Information Classification · 1% confidence The provided document text appears to be an excerpt from a Swiss Commercial Register extract (Handelsregisteramt des Kantons Basel-Stadt) for a company named 'BioVersys AG'. It details corporate information such as the company number (Firmennummer), legal form (Rechtsnatur: Aktiengesellschaft), and historical changes in share capital (Aktienkapital) and registered domicile (Domiziladresse). This type of official corporate registration data does not align with standard SEC filings (like 10-K, ER, IR) or common investor relations documents (like IP, CT, AGM-R). It is a specific type of regulatory/corporate record. Since there is no specific category for 'Commercial Register Extract' and it is a formal, official corporate filing, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it represents official public record information that doesn't fit the other defined categories.
2025-02-13 German
BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE
Regulatory Filings Classification · 1% confidence The document is a press release dated February 11, 2025, announcing a scientific/development milestone for BioVersys AG's BV500 NTM program. It details progress, collaboration support (LifeArc, CF AMR Syndicate), and provides background information on the disease and partners. This type of announcement, focusing on operational progress, research milestones, and partnership updates, is characteristic of an Earnings Release (ER) if it were tied to a quarterly period, or more generally, a news release. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a DIRS or DIV notice, and it provides key highlights of recent operational success rather than a comprehensive management discussion (MDA), the most appropriate classification among the options is Earnings Release (ER), as these often contain operational updates alongside financial highlights, or Regulatory Filing (RNS) as a general announcement. Given the structure and content—a news announcement detailing specific program advancement and quoting management/partners—it strongly resembles an Earnings Release or a general corporate update. Since it is not explicitly stating 'financial results' but rather 'program advancement,' and it is a news detail, it fits best as a general corporate announcement. However, in many databases, significant operational updates that are not full reports are often categorized under ER if they are time-sensitive news releases. Given the options, and the fact that it is a formal announcement of progress rather than a regulatory filing fallback, ER is a strong candidate if it were quarterly, but since it's a specific R&D update, RNS (Regulatory Filings/General Announcement) is the safest fallback for non-standard corporate news. Given the context of financial reporting databases, these milestone announcements are often grouped with ERs or RNS. I will classify it as RNS as it is a general corporate news announcement that doesn't fit the specific financial report categories (10-K, IR, ER) or specific event categories (DIV, DIRS, etc.).
2025-02-11 English
BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
Share Issue/Capital Change Classification · 1% confidence The document is an announcement titled "BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW". It details the pricing, share placement, market capitalization, and intended use of proceeds from an Initial Public Offering (IPO). An IPO is a primary capital-raising and financing activity. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it is an announcement, the core subject matter is the completion of the financing event itself, rather than just announcing the publication of a separate report (which would be RPA/RNS).
2025-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.